CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Life Sciences Review Life Sciences Review | Monday, January 24, 2022
Tweet

TCR² Therapeutics selects Rosemary Harrison as Chief Business and Strategy Officer.


FREMONT, CA: “We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR² as she has proven throughout her career an ability to work closely with multiple commercial functions to identify and execute clear strategic priorities," states Garry Menzel, Ph.D., President and Chief Executive Officer of TCR² Therapeutics. "We look forward to her immediate operational impact as 2022 is a year full of milestones in which our lead program gavo-cel will enter a Phase 2 clinical trial, TC-510 will enter a Phase 1 clinical trial and several other programs; provide opportunities for strategic dialogue.” TCR² Therapeutics Inc., a clinical-stage cell therapy company developing novel T cell therapies for patients with solid tumors, has appointed Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer. In this role, she will support various activities, including commercial strategy, operational planning, corporate partnerships, and long-term growth opportunities.


Dr. Harrison brings over two decades of global experience in strategic planning, portfolio management, and business development to TCR². Before joining the company, she served as Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics, where she was instrumental in the company's November 2021 acquisition by Pfizer for $2.22 billion. Dr. Harrison has held positions in strategy and research at RA Capital Management and as Head of Rare Diseases at Imbria Pharmaceuticals. She formerly worked as the Head of Portfolio Management and Strategy Planning at the Novartis Institutes for Biomedical Research and as a consultant at Bain & Company. She advised on corporate strategic and operational initiatives. Dr. Harrison graduated from The University of Queensland with a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. in Biotechnology.


“TCR2s first-in-class T cell platform is highly differentiated by leveraging the full TCR complex, independent of HLA and has already demonstrated encouraging clinical data in treatment-refractory solid tumors,” states Dr. Harrison. “I am thrilled to be joining TCR2 during such an important period and look forward to working with the outstanding team to focus priorities and support a clear execution plan.”


Weekly Brief

loading
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/rosemary-harrison-joins-tcr-therapeutics-as-chief-business-and-strategy-officer-nwid-701.html